<DOC>
	<DOCNO>NCT02021526</DOCNO>
	<brief_summary>This single-site , open-label , phase II trial C7 , food supplement medical food , development treatment outcome measure glucose transporter type I deficiency ( G1D ) . The primary outcome measure : 1 . Safety tolerability C7 measure change comprehensive blood work , include lipid free fatty acid panel , self-reported side effect clinical exam ; 2 . Changes brain metabolic rate MRI EEG measurement C7 treatment ; 3 . Maintenance ketosis G1D patient ketogenic diet , measure serial ketone level treatment initiation .</brief_summary>
	<brief_title>Triheptanoin ( C7 Oil ) , Food Supplement , Glucose Transporter Type I Deficiency ( G1D )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carbohydrate Metabolism , Inborn Errors</mesh_term>
	<criteria>Diagnosis suspect diagnosis glucose transporter type I deficiency ( G1D ) . On stable ketogenic diet ratio 1:2.5 1:4 OR Stable dietary therapy Males females 30 month 55 year old , inclusive . Subjects history lifethreatening seizure episode , include limited status epilepticus cardiac arrest . Subjects BMI ( body mass index ) great equal 30 exclude . Subjects currently dietary therapy ketogenic diet ( i.e. , medium chain triglyceridesupplemented diet , Atkins diet , low glycemic index diet , etc. ) . Women pregnant breastfeeding may participate . Women plan become pregnant course study , unwilling use birth control prevent pregnancy ( include abstinence ) may participate . Allergy/sensitivity triheptanoin . Previous treatment triheptanoin . Treatment medium chain triglyceride last 30 day . Subjects exhibit sign dementia , diagnose degenerative brain disorder ( Alzheimer 's disease ) would confound assessment cognitive change , opinion investigator . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . Patients metal implant , experience claustrophobia , behaviorally unable still MRS ( magnetic resonance spectroscopy ) imaging ( due seizure ) exclude image portion research . Inability unwillingness subject legal guardian/representative give write informed consent , assent child age 1017 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Months</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>G1D</keyword>
	<keyword>Glut1 Deficiency</keyword>
	<keyword>Glucose Transporter Type 1 Deficiency</keyword>
	<keyword>Glucose Transporter Type I Deficiency</keyword>
</DOC>